Immunotherapy for stage IV melanoma that has spread
Treatments studied
Part of Cancer, Skin clinical trials.
This trial studies an “immune cell” treatment for people with stage IV melanoma that is progressing despite prior care. It may help by boosting the body’s ability to recognize and attack melanoma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed skin cancer diagnosis called melanoma (not a different cancer).
- Your melanoma is stage IV and has spread (metastatic) and is progressing despite treatment.
- You are age 18 or older.
- You can do most daily activities (ECOG score of 0 to 1).
- Your blood protein called albumin is at least 3.0 (a sign your body is in adequate condition).
- You do not have active brain metastases or brain infection related to cancer; previously treated brain spots are only okay if stable for at least 1 month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if injecting two immunotherapy drugs (ipilimumab and nivolumab) just under the skin can help prevent high-risk stage II melanoma from spreading. It is for people who have recently had a thick melanoma removed and have not yet had a sentinel node biopsy.
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
This trial tests a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) for people with melanoma that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
This trial tests whether giving immunotherapy (anti-PD1) before and after surgery can help treat melanoma that has spread to nearby lymph nodes or skin. It is for people whose melanoma can be removed surgically, and who either haven't had systemic treatment before or whose melanoma has returned after prior immunotherapy or targeted therapy.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This trial tests a new combination immunotherapy for people with advanced melanoma. It aims to help those whose cancer has not been controlled by standard treatments.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.